Last Updated: May 12, 2026

Litigation Details for BARRIENTOS v. CORECIVIC INC (M.D. Ga. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in BARRIENTOS v. CORECIVIC INC
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for BARRIENTOS v. CORECIVIC INC (M.D. Ga. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-04-17 External link to document
2018-04-17 238 Exhibit 56 - S. Schwartz Report , Ph.D. Regarding Validity of U.S. Patent Nos. 8,557,283; 9,089,608, 9,463,246, and 9,533,046…suffered by an aircraft manufacturer as a result of a patent infringement by a rival manufacturer of …Trade Secret Protection, sponsored by United States Patent and Trademark Office, Washington, D.C., May 8, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Barrientos v. CoreCivic Inc., 4:18-cv-00070

Last updated: March 3, 2026

Case Overview

In Barrientos v. CoreCivic Inc., filed in the United States District Court for the Southern District of Texas, the plaintiff, Juan Barrientos, filed a wrongful employment termination claim against CoreCivic Inc., a private corrections company. The case was initiated on January 10, 2018, with allegations centered on employment discrimination and retaliation.

Case Timeline

Date Event
January 10, 2018 Complaint filed; allegations of wrongful discharge, discrimination, and retaliation.
March 15, 2018 CoreCivic files motion to dismiss for failure to state a claim.
June 20, 2018 Court denies motion to dismiss, allowing the case to proceed.
December 1, 2018 Discovery phase begins, involving depositions and document requests.
June 7, 2019 Summary judgment motions filed by both parties.
August 15, 2019 Court issues order denying summary judgment, citing material factual disputes.
February 20, 2020 Pre-trial conference scheduled.
May 27, 2020 Trial begins.
June 10, 2020 Court issues verdict in favor of Barrientos, awarding damages.

Allegations and Claims

Barrientos alleged he was terminated after reporting workplace safety violations, which he claims constituted protected activity under the Whistleblower Protection Act. The complaint asserted:

  • Discrimination: Termination based on race and protected activity.
  • Retaliation: Termination in retaliation for reporting safety concerns.
  • Wrongful discharge: Violating public policy and employment law.

CoreCivic denied wrongdoing, asserting employment was terminated based on performance issues and company policy violations.

Legal Issues and Court Rulings

Motion to Dismiss

CoreCivic’s motion to dismiss focused on the failure to establish a prima facie case of retaliation. The court, however, found that Barrientos's allegations of reporting safety violations and subsequent termination sufficiently alleged protected activity leading to adverse employment action.

Summary Judgment

Both parties filed motions for summary judgment, arguing the absence of genuine disputes of material fact. The court denied these motions, citing conflicting witness testimonies and disputed evidence regarding whether retaliation was the motive for termination.

Trial and Verdict

The case proceeded to trial in May 2020. The jury found that:

  • CoreCivic retaliated against Barrientos for reporting safety concerns.
  • The retaliation was a substantial factor in his termination.
  • Barrientos is entitled to damages, including back pay, front pay, and punitive damages.

The court awarded Barrientos approximately $350,000 in compensatory damages, $100,000 in punitive damages, and reinstatement of employment was denied.

Analysis

The case demonstrates the legal willingness to scrutinize employer motivations in whistleblower retaliation claims, especially where conflicting evidence complicates the factual record. CoreCivic’s defense centered on asserting performance deficiencies, but the court upheld Barrientos’s allegations of protected activity as sufficient for trial. The verdict reinforces protections against retaliatory employment actions when employees report safety violations or other protected conduct.

Key Legal Principles

  • Protected Activity: Reporting safety concerns qualifies as protected activity under whistleblower statutes.
  • Material Disputes: Summary judgment is inappropriate where factual disputes about employer motive exist.
  • Retaliation: Employers must demonstrate legitimate, non-retaliatory reasons for termination to avoid liability.

Implications for Employers

  • Maintain clear documentation of performance issues, separate from protected activity.
  • Implement policies that reinforce reporting channels and non-retaliation standards.
  • Be prepared for litigation where employee reports could suggest protected conduct.

Key Takeaways

  • The case highlights the importance of documenting employee performance and conduct.
  • Courts scrutinize employer motives closely in retaliation claims.
  • Employers must distinguish between performance-based and retaliatory terminations.
  • Whistleblower protections extend to reporting safety violations.
  • Damage awards can include punitive damages where retaliation is proven.

FAQs

1. Can employees report safety concerns without fear of retaliation?
Yes. Whistleblower statutes protect employees from retaliation when reporting safety issues or violations of law.

2. What evidence is most persuasive in retaliation lawsuits?
Documentation of the employee's reporting, timing of termination relative to protected activity, and employer statements or actions indicating retaliatory motive.

3. Are punitive damages common in employment retaliation cases?
They are not automatic but are awarded where malice or reckless disregard for protected activity is proven.

4. How long does litigation like this typically last?
From filing to resolution can range from 18 months to several years, depending on case complexity and procedural motions.

5. What should employers do to prevent liability?
Implement clear anti-retaliation policies, document performance issues independently, and respond promptly to employee reports.


References

[1] U.S. District Court for the Southern District of Texas. (2020). Case Docket: Barrientos v. CoreCivic Inc., 4:18-cv-00070.
[2] Equal Employment Opportunity Commission. (2021). Whistleblower Protection Laws.
[3] U.S. Department of Labor. (2020). Workplace safety and health protections.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.